You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Nicorandil reduced coronary events in stable angina

https://doi.org/10.1136/ebm.7.6.169

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) Lancet 359, 1269; The IONA Study Group.. Effect of nicorandil on coronary events in patients with stable angina: the Impact of Nicorandil in Angina (IONA) randomised trial. . Apr 13;. :. –75..
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with stable angina and additional risk factors, is nicorandil more effective than placebo for reducing coronary events?

    Design

    Randomised (allocation concealed*), blinded (clinicians and patients),* placebo-controlled trial with mean follow up of 1.6 years.

    Setting

    226 UK centres (primary care and hospital practices).

    Patients

    5126 patients (mean age 67 y, 76% men) who had stable angina with a history of myocardial infarction (MI), coronary bypass surgery, a definite diagnosis (by angiography) of coronary heart disease (CHD), or a documented positive result on the exercise test. Patients with CHD or a positive result on the exercise test were also required to have additional risk factors, including left ventricular ejection fraction ≤45%, echocardiographical end-diastolic dimension >55 mm, and type 1 or type 2 diabetes. Patients receiving treatment with a sulfonylurea were …

    View Full Text